**Drug list changes effective July 1**

Effective July 1\*, we will make changes to our commercial, Cigna Total Savings, and Legacy drug formularies as well as to the specialty medical drugs we cover to help ensure our customers have access to affordable and quality health care.

By making these updates, we have the opportunity to promote cost-effective and clinically appropriate therapies, coordinate treatment in the right setting, and improve clinical outcomes and affordability.

In April, we will send letters explaining these changes to affected providers and customers. We encourage providers to discuss covered, clinically appropriate alternatives with their affected patients before July 1.

We will send additional communications about hyaluronic acid derivatives and SPRAVATO® to affected providers. Evernorth Behavioral Health will also send a SPRAVATO coverage update to contracted behavioral health providers.

**Reimbursement policy update – Modifier 26 professional component effective July 1**

We routinely review our coverage, reimbursement, and administrative policies for potential updates. In that review, we take into consideration one or more of the following: Evidence-based medicine (EBM), professional society recommendations, Centers for Medicare & Medicaid Services (CMS) guidance, industry standards, and our other existing policies.

As a result of a recent review, we will reduce reimbursement to $5 for Current Procedural Terminology (CPT®) codes billed with modifier 26 when the professional component/technical component (PC/TC) payment indicator is 3 or 9.

This update is effective for claims processed on or after July 1, 2022.

This change aligns with our current reimbursement policy, Modifier 26 Professional Component, and the CMS National Physician Fee Schedule.

**Additional information**

For more information about our policy updates, visit the Cigna for Health Care Professionals website (CignaforHCP.com) > Resources > Coverage Policies > Policy Updates.

**SPRAVATO coverage change effective July 1**

Effective July 1\*, Cigna will change how it covers SPRAVATO®.  Cigna will cover SPRAVATO under the pharmacy benefit but will no longer cover the drug under the medical benefit.

SPRAVATO (esketamine) is a nasal spray for treatment-resistant depression in adults who have not benefited from other treatments and major depressive disorder with acute suicidal ideation or behavior.

For customers who do not have Cigna pharmacy benefits, the pharmacy plan administrator will determine coverage.

**Please note:** This change should not affect most behavioral health providers since Evernorth Behavioral Health has always advised that they should leverage a customer’s pharmacy benefits for SPRAVATO.